Union européenne - français - EMA (European Medicines Agency)

pierre fabre medicament - vinflunine - carcinoma, transitional cell; urologic neoplasms - agents antinéoplasiques - javlor est indiqué en monothérapie pour le traitement des patients adultes avec avancé ou métastatique carcinome à cellules transitionnelles du tractus urothéliales après l’échec d’un régime antérieur contenant du platine. l'efficacité et l'innocuité de la vinflunine n'ont pas été étudiées chez les patients atteints de la condition de performance ≥ 2.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

novartis pharma sas - triclabendazole 250 mg - comprimé - 250 mg - pour un comprimé > triclabendazole 250 mg - autres antitrématodes - classe pharmacothérapeutique - code atc : autres antitrématodes - p02bx.egatenappartient à la famille des benzimidazolés. ce médicament est un antiparasitaire.il est utilisé pour traiter la distomatose hépatique (affection provoquée par la "douve du foie" du mouton).cette maladie est provoquée par un parasite (appelé fasciola hepatica ou fasciola gigantica) que vous avez consommé dans votre alimentation (en général présent sur du cresson sauvage). une fois dans votre organisme, le parasite se fixe sur le foie et provoque la distomatose hépatique.

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as kalceks a.s. - chlorhydrate d'ondansétron dihydraté 2,494 mg/ml - eq. ondansétron 2 mg/ml - solution injectable/pour perfusion - 2 mg/ml - chlorhydrate d'ondansétron dihydraté 2.494 mg/ml - ondansetron

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as kalceks a.s. - chlorhydrate d'ondansétron dihydraté 2,494 mg/ml - eq. ondansétron 2 mg/ml - solution injectable/pour perfusion - 2 mg/ml - chlorhydrate d'ondansétron dihydraté 2.494 mg/ml - ondansetron

Union européenne - français - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil de chlorhydrate de - néoplasmes colorectaux - agents antinéoplasiques - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Union européenne - français - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunosuppresseurs - la polyarthrite rhumatoïde (pr)kineret est indiqué chez les adultes pour le traitement des signes et symptômes de la pr en association avec le méthotrexate, avec une réponse inadéquate au méthotrexate seul. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. fièvre périodique syndromeskineret est indiqué pour le traitement de l'suivantes auto-inflammatoires syndromes de fièvre périodique chez les adultes, les adolescents, les enfants et les nourrissons âgés de 8 mois et plus, avec un poids de 10 kg ou ci-dessus:la cryopyrine syndromes périodiques associés à la (caps)kineret est indiqué pour le traitement de casquettes, y compris les nouveau-nés l'apparition maladie inflammatoire multisystémique (cinca) / chronique infantile neurologique, cutané, syndrome articulaire (cinca)syndrome de muckle-wells (mws)syndrome familial auto-inflammatoires froid (fcas)la fièvre méditerranéenne familiale (fmf)kineret est indiqué pour le traitement de la fièvre méditerranéenne familiale (fmf). kineret doit être administré en association avec la colchicine, le cas échéant. toujours est diseasekineret est indiqué chez les adultes, les adolescents, les enfants et les nourrissons âgés de 8 mois et plus, avec un poids de 10 kg ou au-dessus pour le traitement de la maladie de still, y compris l'arthrite idiopathique juvénile systémique (ajis) et adulte de la maladie de still (aosd), avec systémique active les fonctionnalités de modéré à élevé d'activité de la maladie, ou dans les patients avec la poursuite de l'activité de la maladie après le traitement avec des non-stéroïdiens anti-inflammatoires non stéroïdiens (ains) ou de glucocorticoïdes. kineret peut être administré en monothérapie ou en combinaison avec d'autres médicaments anti-inflammatoires et antirhumatismaux modificateurs de la maladie médicaments (armm).

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - agents antinéoplasiques - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Union européenne - français - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Union européenne - français - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - des sérums et immunoglobulines, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.